logo-loader

Hutchison China MediTech starts late-stage trial on colorectal cancer drug

Published: 08:27 04 Sep 2020 BST

Hutchison China MediTech Limited - Hutchison China MediTech starts late-stage trial on colorectal cancer drug

Hutchison China MediTech Limited (LON:HCM) announced the start of Phase III of trials for fruquintinib, treating metastatic colorectal cancer.

The first patient was dosed on Thursday, while the trial will be rolled out in 130 sites in 10 countries.

READ: Hutchison China MediTech starts phase II study for liver cancer treatment

The US Food and Drug Administration fast-tracked the candidate for this type of cancer in June, while the study design was also reviewed and endorsed by the European Medicines Agency and the Japanese Pharmaceuticals and Medical Devices Agency.

Colorectal cancer starts in either the colon or rectum and is the third most common cancer worldwide, causing more than 860,000 deaths in 2018.

FTSE rises ahead of Easter weekend, JD Sport gains on upbeat outlook -...

The FTSE 100 gained on the final morning of this shortened Easter trading week. Festive cheer was limited though, as Thames Water confirmed shareholders would not provide it with a £500 million rescue package, prompting speculation over the London supplier’s future. On a more positive...

1 hour, 34 minutes ago